公开(公告)号：WO2023028597A1

公开(公告)日：2023-03-02

申请号：PCT/US2022/075535

申请日：2022-08-26

Applicant: YALE UNIVERSITY

Inventor： CAIANIELLO, David ,  DERAMON, Edward ,  SPIEGEL, David

IPC: A61K47/64 ,  A61K45/06 ,  A61K47/62 ,  A61P9/10 ,  C07D249/16 ,  C07K7/50 ,  C07K7/52 ,  C07K16/28

Abstract: The disclosure describes compounds of Formula la, which in non-limiting aspects contain an asialoglycoprotein receptor (ASGPR) binding moiety and an anti-piAR binding moiety. Compounds of Formula la are useful in preventing, treating, and/or ameliorating heart failure in a subject when administered in therapeutically effective amounts.

公开(公告)号：WO2022020652A2

公开(公告)日：2022-01-27

申请号：PCT/US2021/042856

申请日：2021-07-22

Applicant: FOG PHARMACEUTICALS, INC.

Inventor： WHITE, Brian Halbert ,  SI, Yaguang ,  TREMBLAY, Martin Robert ,  CONRADY, Deborah Gail ,  ZHANG, Yue-Mei ,  JEWETT, Ivan Tucker ,  ALFARO-LOPEZ, Lorenzo Josue ,  CAPPUCCI, Sarah Isabelle ,  LI, Zhi

IPC: C07K7/64 ,  C07K7/50 ,  C07K7/54 ,  C07K7/52 ,  A61K38/12

Abstract: Among other things, the present disclosure provides various agents. In some embodiments, provided agents can bind to beta-catenin. In some embodiments, the present disclosure provides technologies for modulating beta-catenin functions. In some embodiments, the present disclosure provides technologies for preventing and/or treating conditions, disorders or diseases associated with beta-catenin. In some embodiments, the present disclosure provides designed amino acids which can provide improved properties and/or activities. In some embodiments, the present disclosure provides agents comprising such amino acids.

公开(公告)号：WO2017004548A1

公开(公告)日：2017-01-05

申请号：PCT/US2016/040744

申请日：2016-07-01

Applicant: AILERON THERAPEUTICS, INC.

Inventor： ANNIS, David Allen ,  GUERLAVAIS, Vincent

IPC: A61K38/12 ,  C07K14/11 ,  C07K7/08 ,  C07K7/52 ,  C07K7/64

CPC classification number: C07K7/06 ,  A61K38/00 ,  C07K14/11

Abstract: The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of viral disease.

Abstract translation: 本发明提供新型拟肽大环化合物和使用这种大环化合物治疗病毒性疾病的方法。

公开(公告)号：WO2011088462A3

公开(公告)日：2011-07-21

申请号：PCT/US2011/021560

申请日：2011-01-18

Applicant: ALBANY MEDICAL COLLEGE ,  ANDERSEN, Thomas, T. ,  JACOBSON, Herbert I. ,  BENNETT, James A. ,  JOSEPH, Leroy ,  BRYAN, Alberto

Inventor： ANDERSEN, Thomas, T. ,  JACOBSON, Herbert I. ,  BENNETT, James A. ,  JOSEPH, Leroy ,  BRYAN, Alberto

IPC: C07K7/52 ,  A61K38/12 ,  A61P35/00

Abstract: The invention relates to compounds that are analogs of a cyclic peptide, cyclo [EKTOVNOGN], AFPep, that has anti-estrotrophic activity. The analogs of the invention include peptides and petidomimetics that inhibit estrogen receptor dependent cell proliferation. The compounds of the invention are useful for treating cell proliferative disorders or physiological conditions characterized by undesirable or unwanted estrogen induced cell proliferation, including breast cancer.

公开(公告)号：WO2008035093A3

公开(公告)日：2008-10-02

申请号：PCT/GB2007003592

申请日：2007-09-20

Applicant: LEXCICON LTD ,  NEW ROGER

Inventor： NEW ROGER

IPC: C07K7/52 ,  A61K38/12

CPC classification number: C07K7/64 ,  A61K38/00

Abstract: An internally-constrained cyclic oligopeptide comprising a ring of at least six amino acids for specifically binding to a target ligand, wherein the ring comprises a plurality of amino acid domains, each domain comprising at least two epitope-forming amino acids, and two or more associating functional groups positioned so that they form one or more intra-cyclic associations; whereby the cyclic oligopeptide is constrained in a single conformation so that the epitope-forming amino acids form an epitope in each domain, each epitope being capable of specifically binding to a target ligand.

Abstract translation: 包含至少六个氨基酸的环的内部限制性环状寡肽，用于特异性结合靶配体，其中所述环包含多个氨基酸结构域，每个结构域包含至少两个表位形成氨基酸，以及两个或多个 将功能组定位成使得它们形成一个或多个内循环关联; 其中环状寡肽被限制在单个构象中，使得表位形成氨基酸在每个结构域中形成表位，每个表位能够特异性结合靶配体。

公开(公告)号：WO01097860A2

公开(公告)日：2001-12-27

申请号：PCT/US2001/020108

申请日：2001-06-21

IPC: C07D249/14 ,  A61K31/138 ,  A61K31/4168 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/454 ,  A61K31/5377 ,  A61K31/569 ,  A61K31/57 ,  A61K31/58 ,  A61K38/00 ,  A61K38/04 ,  A61K38/21 ,  A61K41/00 ,  A61K45/00 ,  A61K51/00 ,  A61N5/06 ,  A61N5/10 ,  A61P9/14 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P41/00 ,  A61P43/00 ,  C07D215/46 ,  C07D233/91 ,  C07J1/00 ,  C07J7/00 ,  C07J33/00 ,  C07K7/52 ,  A61K51/08

CPC classification number: A61K51/088 ,  A61K41/0038 ,  A61K51/082 ,  A61K51/1251

Abstract: The present invention describes novel compounds of the formula (I):(Q)d-Ln-Ch, useful for the diagnosis and treatment of cancer in combination therapy in a patient. The present invention provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety

Abstract translation: 本发明描述了用于患者联合治疗中癌症诊断和治疗的式（I）：（Q）d-Ln-Ch的新型化合物。 本发明提供了可用于治疗类风湿性关节炎的新化合物。 药物由靶向部分组成，其靶向部分与血管生成期间上调的受体结合，任选的连接基团和治疗有效的放射性同位素或诊断有效的可成像部分

公开(公告)号：WO2022212700A2

公开(公告)日：2022-10-06

申请号：PCT/US2022/022817

申请日：2022-03-31

Applicant: PROTAGONIST THERAPEUTICS, INC.

Inventor： BOURNE, Gregory Thomas ,  BHANDARI, Ashok

IPC: C07K7/50 ,  A61P3/02 ,  C07K7/52 ,  C07K7/54 ,  C07K7/64 ,  C07K14/575 ,  A61K38/00 ,  A61P3/00

Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including both peptide monomers and peptide dimers, and conjugates and derivatives thereof, as well as compositions comprising the peptide analogues, and to the use of the peptide analogues in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of erythrocytoses, such as polycytemia vera, iron overload diseases such as hereditary hemochromatosis, iron-loading anemias, and other conditions and disorders described herein.

公开(公告)号：WO2020053255A1

公开(公告)日：2020-03-19

申请号：PCT/EP2019/074195

申请日：2019-09-11

Applicant: TECHNISCHE UNIVERSITÄT MÜNCHEN

Inventor： OSL, Theresa ,  WESTER, Hans-Jürgen ,  SCHOTTELIUS, Margret

IPC: C07K7/52 ,  A61K38/00 ,  G01N33/68

Abstract: The present disclosure relates to imaging and endoradiotherapy of diseases involving chemokine receptor 4 (CXCR4). Provided are compounds which bind or inhibit CXCR4 and furthermore carry at least one moiety which is amenable to labeling. Provided are also medical uses of such compounds.

公开(公告)号：WO2017118491A1

公开(公告)日：2017-07-13

申请号：PCT/EP2016/050935

申请日：2016-01-19

Applicant: PEPTINOV SAS ,  CONSERVATOIRE NATIONAL DES ARTS ET METIERS

Inventor： DESALLAIS, Lucille ,  ZAGURY, Jean-François

IPC: C07K7/08 ,  C07K7/52 ,  C07K7/64 ,  A61K38/10 ,  A61K38/12 ,  A61K39/385 ,  A61K39/00

CPC classification number: C07K7/52 ,  A61K38/10 ,  A61K38/12 ,  A61K39/0008 ,  A61K39/385 ,  A61K2039/545 ,  A61K2039/55566 ,  A61K2039/6081 ,  C07K7/08 ,  Y02A50/412

Abstract: The present invention relates to a method for treatment of self-protein-related diseases, or for vaccinating or immunizing against self-protein related diseases, in an individual during a treatment period, comprising performing several administrations of an effective amount of a peptide derived from the self-protein to the individual, wherein the administrations are distributed all along the treatment period.

Abstract translation: 本发明涉及治疗期间个体中自身蛋白质相关疾病的治疗或用于接种或免疫自身蛋白质相关疾病的方法，包括进行几次 有效量的自身蛋白质衍生的肽给予个体，其中给药全程分布于治疗期。

公开(公告)号：WO2016057624A1

公开(公告)日：2016-04-14

申请号：PCT/US2015/054407

申请日：2015-10-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： SUN, Li-Qiang ,  ZHAO, Qian ,  MULL, Eric ,  GILLIS, Eric P. ,  SCOLA, Paul Michael

IPC: C07K7/52 ,  C07K7/56 ,  A61K38/12 ,  G01N33/68

CPC classification number: C07K7/64 ,  A61K38/00 ,  A61K38/10 ,  A61K38/12 ,  A61K45/06 ,  C07K7/08 ,  C07K7/56 ,  G01N33/574 ,  G01N2333/70532 ,  G01N2500/02 ,  G01N2800/26 ,  Y02A50/463

Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.